BMS 4Q Revenues: $4.4 billion (+6%) 4Q Earnings: $735.0 million (-20%) YTD Revenues: $16.4 billion (-7%) YTD Earnings: $2.6 billion (+3%) Comments: U.S. revenues increased 1% to $2.3 billion in the quarter and international revenues increased 11% to $2.2 billion. Yervoy sales grew 23% to $260 million. Onglyza/Kombiglyze sales were $224 million, up 13%. Sprycel sales grew 30% to $365 million, and Orencia sales were up 22% to $397 million. Abilify sales were down 22% to $635 million, due to l...